Clinical Practice Points
- •To date, the prognostic role of prior bladder cancer (BCa) among patients with upper tract urothelial carcinoma (UTUC) is still poorly addressed.
- •We aimed to investigate the role of prior BCa on any recurrence (aR), distant metastasis (DM), and bladder recurrence following RNU among low-grade (LG) and high-grade (HG) UTUC patients.
- •We retrospectively analyzed a multicenter cohort of 1,580 patients treated with radical nephroureterectomy (RNU) for UTUC. Median follow-up was 4 years.
- •The Kaplan-Meier curves were applied to assess aR, DM, and bladder recurrence, computed from the time of RNU. Multivariable Cox models were generated to predict the risk of aR, DM, and bladder recurrence. All analyses were stratified by tumor grade (LG and HG), site of recurrence (aR, DM, and bladder recurrence), and prior history of BCa (no prior BCa, non-muscle-invasive [NMIBC], and muscle-invasive bladder cancer [MIBC]).
- •Both LG and HG UTUC patients with prior BCa had a significantly increased risk of aR and bladder recurrence on multivariable Cox models, compared to individuals with no prior BCa.
- •The main strength of our paper is represented by the fact that this is the first study in which analyses were stratified according to both UTUC grade and muscle-invasiveness of prior BCa history. Additionally, our cohort represent the largest cohort available in literature that evaluates the role of prior BCa on aR after RNU for UTUC.
- •The present study is limited by its retrospective design and the lack of some information on prior BCa, such as multifocality or previous intravesical therapy.
Abstract
Introduction
Patients and Methods
Results
Conclusions
Keywords
Abbreviations:
UTUC (upper tract urothelial carcinoma), RNU (radical nephroureterectomy), BCa (bladder cancer), AC (adjuvant chemotherapy), NMIBC (non-muscle-invasive bladder cancer), MIBC (muscle-invasive bladder cancer), HG (high grade), LG (low grade), CI (confidence interval), HR (hazard ratio)Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerReferences
- Upper urinary tract tumors: variant histology vs. urothelial carcinoma.Clin Genitourin Cancer. 2020; (Published online)https://doi.org/10.1016/j.clgc.2020.11.004
- Upper Tract Urothelial Neoplasms : Incidence And Survival During The Last 2 Decades. 2000; 164: 1523-1525
- Stage migration for upper tract urothelial cell carcinoma.Clin Genitourin Cancer. 2020; (Published online)https://doi.org/10.1016/j.clgc.2020.09.007
- Neoadjuvant vs. adjuvant chemotherapy for upper tract urothelial carcinoma.Urol Oncol Semin Orig Investig. 2020; 38: 684.e9-684.e15https://doi.org/10.1016/j.urolonc.2020.03.008
- Urothelial carcinoma of the renal pelvis and ureter: does location make a difference?.Clin Genitourin Cancer. 2020; 18 (e1): 45-49https://doi.org/10.1016/j.clgc.2019.10.023
- Outcome prediction following radical nephroureterectomy for upper tract urothelial carcinoma.Urol Oncol Semin Orig Investig. 2021; 39: 133.e9-133.e16https://doi.org/10.1016/j.urolonc.2020.08.021
Martini A, Daza J, Poltiyelova E, et al. Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma. Published online 2019:665-671. doi:10.1111/bju.14719
- European Association of urology guidelines on upper urinary tract urothelial carcinoma : 2020 update.Eur Urol. 2021; 9: 80-81https://doi.org/10.1016/j.eururo.2020.05.042
Zamboni S, Foerster B, Abufaraj M, et al. Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. Published online 2019:1-8. doi:10.1111/bju.14751
- Urothelial carcinoma of the bladder and the upper tract : disparate twins.JURO. 2013; 189: 1214-1221https://doi.org/10.1016/j.juro.2012.05.079
- Genetic differences between bladder and upper urinary tract carcinoma : implications for therapy.Eur Urol Oncol. 2021; (Published online): 1-10https://doi.org/10.1016/j.euo.2020.12.007
Kuroiwa K, Inokuchi J, Nishiyama H, et al. Impact of previous, simultaneous or subsequent bladder cancer on prognosis after radical nephroureterectomy for upper urinary tract urothelial carcinoma. 2019;202(December):1127-1135.
- Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers.Eur Urol. 2018; 73: 560-569https://doi.org/10.1016/j.eururo.2017.12.018
- The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumors.Eur Urol. 2016; (Published online)https://doi.org/10.1016/j.eururo.2016.02.028
Novara G, Matsumoto K, Kassouf W, et al. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract : an international validation study. 2010;57:1064-1071. doi:10.1016/j.eururo.2009.12.029
- Association between lymphovascular invasion and oncological outcome in node-negative upper tract urothelial carcinoma with different stage.Urol Oncol Semin Orig Investig. 2021; 39: 132.e13-132.e26https://doi.org/10.1016/j.urolonc.2020.08.008
Colin P, Ouzzane A, Yates DR, et al. Influence of positive surgical margin status after radical nephroureterectomy on upper urinary tract urothelial carcinoma survival. Published online 2012:3613-3620. doi:10.1245/s10434-012-2453-9
- Neoadjuvant vs. adjuvant chemotherapy for upper tract urothelial carcinoma: a microsimulation model.Clin Genitourin Cancer. 2020; (Published online)https://doi.org/10.1016/j.clgc.2020.10.001
- Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma : Frequency, risk factors, and surveillance.URO. 2011; 29: 130-136https://doi.org/10.1016/j.urolonc.2009.06.003
Rouprêt M. Anatomical location of urothelial carcinomas of the urinary tract leads to perspectives of specific treatment. Published online 2007:595-599.
Belhadj Y, Grande P, Seisen T, et al. Bladder mapping of tumour recurrence after radical nephroureterectomy for upper tract urothelial carcinoma and its in fl uence on oncological outcomes. Published online 2019. doi:10.1111/bju.14647
Mullerad M, Russo P, Golijanin D, et al. Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma. 2004;172(December):2177-2181. doi:10.1097/01.ju.0000144505.40915.98
- Prognostic value of prior history of urothelial carcinoma of the bladder in patients with upper urinary tract urothelial carcinoma : results from a retrospective multicenter study.World J Urol. 2015; (Published online): 1005-1013https://doi.org/10.1007/s00345-014-1363-9
- Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma □.URO. 2014; 31: 1615-1620https://doi.org/10.1016/j.urolonc.2012.03.004
- Effects of previous or synchronous non-muscle invasive bladder cancer on clinical results after radical nephroureterectomy for upper tract urothelial carcinoma: a multi-institutional study. 2015; 12: 223-229
D M, Colin P, Zerbib M, Ruffion A, Long J, Crouzet S. Influence of previous or synchronous bladder cancer on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma. 2014;32:1-8. doi:10.1016/j.urolonc.2012.08.010
Raman JD, Ng CK, Boorjian SA. Bladder cancer after managing upper urinary tract transitional cell carcinoma : predictive factors and pathology. Published online 2005. doi:10.1111/j.1464-410X.2005.05804.x
